|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2006-11-13
|
|
pubmed:abstractText |
In order to characterize the antiviral activity of human TRIM5alpha in more detail human derived indicator cell lines over expressing wild type human TRIM5alpha were generated and challenged with HIV-1 and HIV-2 viruses pseudotyped with HIV envelope proteins in comparison to VSV-G pseudotyped particles. HIV envelope protein pseudotyped particles (HIV-1[NL4.3], HIV-1[BaL]) showed a similar restriction to infection (12 fold inhibition) compared to VSV-G pseudotyped viruses after challenging TZM-huTRIM5alpha cells. For HIV-2 a stronger restriction to infection was observed when the homologous envelope protein Env42S was pseudotyped onto these particles compared to VSV-G pseudotyped HIV-2 particles (8.6 fold inhibition versus 3.4 fold inhibition). It has been shown that HIV-2 is restricted by the restriction factor Lv2, acting on capsid like TRIM5alpha. A mutation of amino acid 73 (I73V) of HIV-2 capsid renders this virus Lv2-insensitive. Lv2-insensitive VSV-G pseudotyped HIV-2/I73V particles showed a similar restriction to infection as did HIV-2[VSV-G] particles (4 fold inhibition). HIV-2 envelope protein (Env42S)-pseudotyped HIV-2/I73V particles revealed a 9.3 fold increase in infection in TZM cells but remained restricted in TZM-huTRIM5alpha cells (80.6 fold inhibition) clearly indicating that at least two restriction factors, TRIM5alpha and Lv2, act on incoming HIV-2 particles. Further challenge experiments using primary isolates from different HIV-1 subtypes and from HIV-1 group O showed that wild type human TRIM5alpha restricted infection independent of coreceptor use of the infecting particle but to variable degrees (between 1.2 and 19.6 fold restriction).
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-10357466,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-11435571,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-12019106,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-12154231,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-12368468,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-12547912,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-12554640,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-12954230,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-14747565,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-14985764,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-15113921,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-15249685,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-15252204,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-15280539,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-15321704,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-15479815,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-15596813,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-15610729,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-15661166,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-15709033,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-15767395,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-15994780,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-16014904,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17087820-16140735
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1742-4690
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
79
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17087820-Capsid,
pubmed-meshheading:17087820-Carrier Proteins,
pubmed-meshheading:17087820-Cell Line,
pubmed-meshheading:17087820-Gene Products, env,
pubmed-meshheading:17087820-HIV-1,
pubmed-meshheading:17087820-HIV-2,
pubmed-meshheading:17087820-HeLa Cells,
pubmed-meshheading:17087820-Humans,
pubmed-meshheading:17087820-Membrane Fusion,
pubmed-meshheading:17087820-Membrane Glycoproteins,
pubmed-meshheading:17087820-Viral Envelope Proteins
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Human TRIM5alpha mediated restriction of different HIV-1 subtypes and Lv2 sensitive and insensitive HIV-2 variants.
|
|
pubmed:affiliation |
Department of Virology, University of Heidelberg, Im Neuenheimer Feld 324, D-69120 Heidelberg, Germany. patrick.kaumanns@med.uni-heidelberg.de
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
